Levodopa-induced dyskinesia in Parkinson's disease: pathogenesis and emerging treatment strategies

DK Kwon, M Kwatra, J Wang, HS Ko - Cells, 2022 - mdpi.com
The most commonly used treatment for Parkinson's disease (PD) is levodopa, prescribed in
conjunction with carbidopa. Virtually all patients with PD undergo dopamine replacement …

Sleep and circadian rhythms in Parkinson's disease and preclinical models

J Hunt, EJ Coulson, R Rajnarayanan, H Oster… - Molecular …, 2022 - Springer
The use of animals as models of human physiology is, and has been for many years, an
indispensable tool for understanding the mechanisms of human disease. In Parkinson's …

[HTML][HTML] Lower urinary tract symptoms in depression: a review

DJ Anderson, A Aucoin, CR Toups… - Health psychology …, 2023 - ncbi.nlm.nih.gov
Abstract Lower Urinary Tract Symptoms (LUTS) are frequently present in the general
population as patients age with approximately a third of individuals experiencing LUTS …

COMT Inhibitors in the Management of Parkinson's Disease

M Fabbri, JJ Ferreira, O Rascol - CNS drugs, 2022 - Springer
Levodopa treatment remains the gold standard for Parkinson's disease, but shortcomings
related to the pharmacological profile, notably, oral administration and the consequent …

Revolutionizing our understanding of Parkinson's disease: Dr. Heinz Reichmann's pioneering research and future research direction

M Tanaka, L Vécsei - Journal of Neural Transmission, 2024 - Springer
Millions of individuals around the world are afflicted with Parkinson's disease (PD), a
prevalent and incapacitating neurodegenerative disorder. Dr. Reichmann, a distinguished …

Redefining the strategy for the use of COMT inhibitors in Parkinson's disease: the role of opicapone

P Jenner, JF Rocha, JJ Ferreira, O Rascol… - Expert Review of …, 2021 - Taylor & Francis
Introduction Levodopa remains the gold-standard Parkinson's disease (PD) treatment, but
the inevitable development of motor complications has led to intense activity in pursuit of its …

Newly approved and investigational drugs for motor symptom control in Parkinson's disease

DG Di Luca, NGD Reyes, SH Fox - Drugs, 2022 - Springer
Motor symptoms are a core feature of Parkinson's disease (PD) and cause a significant
burden on patients' quality of life. Oral levodopa is still the most effective treatment, however …

Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations

M Regensburger, CW Ip, Z Kohl, C Schrader… - Journal of Neural …, 2023 - Springer
Inhibitors of monoamine oxidase B (MAO-B) and catechol-O-methyltransferase (COMT) are
major strategies to reduce levodopa degradation and thus to increase and prolong its effect …

Advances in the pharmacological and non-pharmacological management of non-motor symptoms in Parkinson's disease: an update since 2017

DJV Wamelen, K Rukavina… - Current …, 2023 - benthamdirect.com
Background: Non-motor symptoms (NMS) are an important and ubiquitous determinant of
quality of life in Parkinson's disease (PD). However, robust evidence for their treatment is still …

What is the impact of catechol-O-methyltransferase (COMT) on Parkinson's disease treatment?

A Salamon, D Zádori, L Szpisjak… - Expert Opinion on …, 2022 - Taylor & Francis
Parkinson's disease (PD) is the second most common neurodegenerative disorder
worldwide [1]. From the pathological perspective, the etiology of the disease is the death of …